| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 06/03/2024 | 14:05 | GlobeNewswire Inc. | Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024 | NASDAQ:SPRO | Spero Therapeutics Inc |
| 28/02/2024 | 14:05 | GlobeNewswire Inc. | Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections | NASDAQ:SPRO | Spero Therapeutics Inc |
| 26/02/2024 | 14:05 | GlobeNewswire Inc. | Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference | NASDAQ:SPRO | Spero Therapeutics Inc |
| 09/02/2024 | 22:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SPRO | Spero Therapeutics Inc |
| 06/02/2024 | 02:53 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SPRO | Spero Therapeutics Inc |
| 05/02/2024 | 22:50 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:SPRO | Spero Therapeutics Inc |
| 31/01/2024 | 22:05 | GlobeNewswire Inc. | Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:SPRO | Spero Therapeutics Inc |
| 05/01/2024 | 14:05 | GlobeNewswire Inc. | Spero Therapeutics Provides Corporate Update and 2024 Outlook | NASDAQ:SPRO | Spero Therapeutics Inc |
| 02/01/2024 | 14:05 | GlobeNewswire Inc. | Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections | NASDAQ:SPRO | Spero Therapeutics Inc |
| 15/11/2023 | 22:15 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:SPRO | Spero Therapeutics Inc |
| 13/11/2023 | 22:50 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:SPRO | Spero Therapeutics Inc |
| 13/11/2023 | 22:05 | GlobeNewswire Inc. | Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update | NASDAQ:SPRO | Spero Therapeutics Inc |
| 13/11/2023 | 22:02 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:SPRO | Spero Therapeutics Inc |
| 13/11/2023 | 12:45 | IH Market News | Monday’s Wall Street Highlights: Boeing, Novo Nordisk, Moody’s, StoneCo, and more | NASDAQ:SPRO | Spero Therapeutics Inc |
| 06/11/2023 | 14:05 | GlobeNewswire Inc. | Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023 | NASDAQ:SPRO | Spero Therapeutics Inc |
| 01/11/2023 | 21:05 | GlobeNewswire Inc. | Spero Therapeutics to Present at Upcoming November Investor Conferences | NASDAQ:SPRO | Spero Therapeutics Inc |
| 01/11/2023 | 13:05 | GlobeNewswire Inc. | Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer | NASDAQ:SPRO | Spero Therapeutics Inc |
| 16/10/2023 | 22:01 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:SPRO | Spero Therapeutics Inc |
| 20/09/2023 | 22:05 | GlobeNewswire Inc. | Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor Conference | NASDAQ:SPRO | Spero Therapeutics Inc |
| 06/09/2023 | 14:05 | GlobeNewswire Inc. | Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference | NASDAQ:SPRO | Spero Therapeutics Inc |
| 01/09/2023 | 22:11 | Edgar (US Regulatory) | Form ARS - Annual Report to Security Holders | NASDAQ:SPRO | Spero Therapeutics Inc |
| 01/09/2023 | 22:08 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:SPRO | Spero Therapeutics Inc |
| 22/08/2023 | 23:27 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:SPRO | Spero Therapeutics Inc |
| 10/08/2023 | 22:05 | GlobeNewswire Inc. | Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update | NASDAQ:SPRO | Spero Therapeutics Inc |
| 03/08/2023 | 14:05 | GlobeNewswire Inc. | Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 | NASDAQ:SPRO | Spero Therapeutics Inc |
| 31/07/2023 | 18:59 | Dow Jones News | Spero Therapeutics Shares Rise 14% After Special Protocol Assessment Agreement With FDA | NASDAQ:SPRO | Spero Therapeutics Inc |
| 31/07/2023 | 14:51 | Dow Jones News | Spero Therapeutics in Special Protocol Assessment Agreement for Phase 3 Trial of Tebipenem HBr | NASDAQ:SPRO | Spero Therapeutics Inc |
| 31/07/2023 | 14:05 | GlobeNewswire Inc. | Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr | NASDAQ:SPRO | Spero Therapeutics Inc |
| 14/06/2023 | 14:31 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:SPRO | Spero Therapeutics Inc |
| 14/06/2023 | 14:13 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:SPRO | Spero Therapeutics Inc |